We can’t show the full text here under this license. Use the link below to read it at the source.
Longitudinal quantification of serum SARS-CoV-2 neutralising antibodies, pro-inflammatory cytokines, NfL and GFAP before and after breakthrough COVID-19 infection in CNS neuroimmunological diseases: a prospective observational study
Changes in COVID-19 antibodies, inflammation markers, and brain injury proteins before and after breakthrough infection in people with central nervous system immune diseases
AI simplified
Abstract
Sixty-one patients with central nervous system neuroimmunological diseases participated in the study.
- Patients on anti-CD20 or sphingosine-1-phosphate-receptor modulators exhibited significantly lower levels of neutralizing antibodies following the fourth vaccine dose and after COVID-19 infection compared to those on other immunotherapies.
- No significant changes were observed in the levels of interleukin-6 and tumor necrosis factor between baseline and post-COVID-19 infection.
- In patients with relapsing-remitting multiple sclerosis and neuromyelitis optica spectrum disorder, and levels did not differ between baseline and post-COVID-19 infection.
AI simplified
Key numbers
2.1%
Decrease in levels post-
Median levels in patients on after .
1.9%
Decrease in levels post-COVID-19 infection
Median levels in patients on after COVID-19 infection.
61 patients
Study population size
Total number of patients included in the analysis.